AustraliaDaily Briefs

Daily Brief Australia: Neuren Pharmaceuticals, Kinatico and more

In today’s briefing:

  • S&P/​​​​​​​ASX Index Rebalance Preview: Potential Changes, Impact, Shorts & Positioning
  • Kinatico Ltd – Q3 SaaS Growth Demonstrates the Flex Potential

S&P/​​​​​​​ASX Index Rebalance Preview: Potential Changes, Impact, Shorts & Positioning

By Brian Freitas

  • The review period for the June rebalance of the S&P/ASX family of indices ends tomorrow and we expect two changes for the S&P/ASX 200 (AS51 INDEX)
  • Impact of passive trading on the stocks varies between 4.3-11 days of ADV. Short interest on the potential adds is small while there are significant shorts on the potential deletes.
  • We expect there is pre-positioning on at least three of the four stocks. In some cases that is small, while it could be a lot larger in other stocks.

Kinatico Ltd – Q3 SaaS Growth Demonstrates the Flex Potential

By Research as a Service (RaaS)

  • Kinatico Ltd (ASX:KYP) is a ‘Know Your People” regtech company providing workforce compliance monitoring and management technology and services.
  • The company recently reported Q3 NPAT of $0.4m and positive cash flow of $0.2m, excluding buyback expenditure.
  • Q3 sales were a record $7.0m, including $1.5m of SaaS revenue, which was up 143% on the previous corresponding period (pcp) and 51% on the prior quarter.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars